A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Adenomatous Polyposis Coli

In brief

The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.

Key facts

Study ID

NCT01187901

Run by

University of Utah

People needed

92

Starts

2010-04-01

Expected to finish

2014-07-01

Last updated by the study team

2016-06-17

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are 18 years or older with a clinical or genetic diagnosis of FAP or attenuated FAP.
• Presence of duodenal polyps with a sum of diameters ≥ 5mm.
• Minimum of two weeks since any major surgery
• WHO performance status ≤1
• Adequate bone marrow function as show by: normal leukocyte count, platelet count ≥ 120 x 109/L, Hgb > 12 g/dL
• Adequate liver function as shown by: normal serum bilirubin(≤ 1.5 Upper Limit Normal {ULN}) and serum transaminases (≤ 2.0 ULN)
• Patient must discontinue taking any Nonsteroidal anti-inflammatory drugs (NSAIDS) within one month of treatment initiation.
• Patients must be able to provide written informed consent.

You may not qualify if…

• Prior treatment with any investigational drug within the preceding 4 weeks.
• Malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skins.
• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as determined by the Principal Investigator such as:
• Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia
• Severely impaired lung function
• Any active (acute or chronic) or uncontrolled infection/ disorders.
• Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy
• Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
• Screening clinical laboratory values that indicate any of the following:
• anemia
• thrombocytopenia
• leucopenia
• elevations of transaminases greater than 2X ULN
• elevation of bilirubin > 1.5 X ULN
• alkaline phosphatase elevation > 1.5 X ULN
• increased creatinine, urinary protein, or urinary casts outside the clinically normal range.
• Gastrointestinal bleeding (symptoms including dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia or abdominal pain will require clinical assessment to rule out gastrointestinal bleeding).
• Patient who is currently taking any anti-coagulation medication.
• Women who are pregnant or breast feeding.
• Patients with a known hypersensitivity to sulindac or erlotinib or to their excipients

Where it is running

• Huntsman Cancer Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.